SCHEMBL2716593

SCHEMBL2716593

CN1CCC(NC(=O)c2ccc([N+](=O)[O-])cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
LMNA P02545 2/20 0.60
DRD4 P21917 1/20 0.55
MMP2 P08253 1/20 0.53
ANPEP P15144 1/20 0.53
HPGD P15428 1/20 0.52
PKM P14618 1/20 0.52
POLB P06746 2/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
EPHX2 P34913 2/20 0.50
HTR1A P08908 1/20 0.50
HTR1D P28221 1/20 0.50
HTR1B P28222 1/20 0.50
HTR1F P30939 1/20 0.50
THRB P10828 1/20 0.50
HSP90AA1 P07900 1/20 0.49
HSP90AB1 P08238 1/20 0.49
SLC6A5 Q9Y345 1/20 0.49
HDAC4 P56524 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28975685 0.87 NPC1 (0.57) ALDH1A1DRD4MMP2ANPEPPOLB
SCHEMBL30583813 0.87 NPC1 (0.57) ALDH1A1DRD4MMP2ANPEPPOLB
SCHEMBL30583812 0.87 NPC1 (0.57) ALDH1A1DRD4MMP2ANPEPPOLB
SCHEMBL16372164 0.84 PKM (0.63) ALDH1A1DRD4PKMPOLBMEN1
SCHEMBL10139158 0.84 SLC6A5 (0.50) ALDH1A1LMNAMMP2ANPEPHPGD
SCHEMBL11359493 0.83 ALDH1A1 (0.62) ALDH1A1DRD4POLB
SCHEMBL9835734 0.82 KMT2A (0.66) ALDH1A1LMNAHPGDPOLBMEN1
SCHEMBL15434058 0.82 POLB (0.57) ALDH1A1LMNADRD4HPGDPKM
SCHEMBL26758000 0.82 ALDH1A1 (0.58) ALDH1A1LMNAPKMPOLBMEN1
SCHEMBL14110292 0.81 KMT2A (0.63) ALDH1A1DRD4MMP2ANPEPPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021074251-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER SENTINEL ONCOLOGY LIMITED (GB) 2021-04-22 WO disclosed
CN-102746175-B Substituted pyrimidodiazepines useful as PLK1 inhibitors TAKAEDA CHEMICAL IND LTD 2014-01-15 CN disclosed
WO-2012059932-A1 2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-05-10 WO disclosed
CN-101636399-A Substituted pyrimido diazepines  useful as PLK1 inhibitors HOFFMANN LA ROCHE 2010-01-27 CN disclosed
EP-2139892-A1 SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS F. Hoffmann-Roche AG (CH) 2010-01-06 EP disclosed
US-7517873-B2 Substituted pyrimidodiazepines HOFFMAN-LA ROCHE INC. (US) 2009-04-14 US disclosed
WO-2008113711-A1 SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-09-25 WO disclosed
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES PLK1, CCNI, CDK1 ALDH1A1 1365/4885LMNA 1758/4885DRD4 1929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.